수니티닙
Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor used as an active pharmaceutical ingredient in anti-cancer medications. It was the first cancer drug simultaneously approved for two different indications.
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 557795-19-4
Sunitinib malate
active pharmaceutical ingredient
Betahistine hydrochloride
active pharmaceutical ingredient
(1S,5R)-1,2,3,4,5,6-Hexahydro-1,5-methano-8H-pyrido(1,2-a)(1,5)diazocin-8-one
active pharmaceutical ingredient
Piretanide
loop diuretic active pharmaceutical ingredient
Methoxyphenamine hydrochloride
beta-adrenergic receptor agonist
(E)-Sunitinib
active pharmaceutical ingredient
Sunitinib acid
Pharmaceutical intermediate for sunitinib synthesis
3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
research reagent for kinase inhibition
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WINHZLLDWRZWRT-ATVHPVEESA-N
CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C